Across multiple cancer types, including renal cell carcinoma, bladder cancer, and non-small cell lung cancer, the levels of plasma cells producing IgG and IgA correlate with the prognosis of ICI therapy [41, 66, 67]. The gene discussed is CD79A; the disease is cancer.